Probing the Role of Alzheimer’s Disease Risk Gene Using Human-Induced Pluripotent Stem Cells and Transgenic Animal Models
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 2559
Special Issue Editor
Interests: cellular and molecular mechanisms of Alzheimer’s disease (AD) using human induced pluripotent stem cell models; how AD risk genes identified by genome-wide association studies contribute to the regulation of neuronal electrical activity and synaptic plasticity
Special Issue Information
Dear Colleagues,
Alzheimer’s disease (AD) is the leading cause of cognitive impairment and dementia worldwide. Despite the identification of numerous AD risk genes through genome-wide association studies in the last 10 years, a comprehensive understanding of AD pathogenesis remains elusive. Importantly, one out of three AD risk genes is predominantly expressed by a unique cell type of the adult human brain. Therefore, understanding the role of AD risk genes in the pathophysiology of AD requires the use of an appropriate model system allowing the manipulation of gene expression in a cell-type-specific fashion. Therefore, this Special Issue aims to publish original research and review articles focused on the study of AD risk genes using both hiPSC-derived cells and transgenic animal models, with a special emphasis on models harboring genetic modifications in specific cell types.
Dr. Marcos R. Costa
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- human induced pluripotent stem cells (hiPSCs)
- hiPSC-derived neurons (hiNs)
- hiPSC-derived astrocytes (hiAs)
- hiPSC-derived microglia (hiMGs)
- cerebral organoids
- amyloidopathy
- tauopathy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
